Консенсус керівних настанов з клінічної практики ISPAD 2018 р. Розділ 2. Стадії діабету 1 типу у дітей і підлітків

Pociot F, Norgaard K, Hobolth N, Andersen O, Nerup J. A nationwide population-based study of the familial aggregation of type 1 (insulin- dependent) diabetes mellitus in Denmark. Danish Study Group of Diabetes in Childhood. Diabetologia. 1993;36(9):870-5.

Nistico L, lafusco D, Galderisi A, et al. Emerging effects of early envi¬ronmental factors over genetic background for type 1 diabetes sus¬ceptibility: evidence from a Nationwide Italian Twin Study. J Clin Endocrinol Metab. 2012;97(8):E1483-E1491.

Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. N Engl J Med. 1984;311(3):149-52.

Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10): 1964-74.

Ziegler AG, Rewers M, Simell O, etal. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-9.

Harjutsalo V, Reunanen A, Tuomilehto J. Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes. 2006;55(5):1517-24.

Barrett JC, Clayton DG, Concannon P, et al. Genome-wide associa¬tion study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6):703-7.

Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59(5):1134-48.

Lambert AP, Gillespie KM, Thomson G, et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004;89(8):4037-43.

Nguyen C, Varney MD, Harrison LC, Morahan G. Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. Diabetes. 2013;62(6): 2135-40.

Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57(4):1084-92.

Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad SciUSA. 2006;103(38):14074-9.

Pociot F, Lernmark A. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331-9.

Winkler C, Krumsiek J, Buettner F, et al. Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabe¬tes. Diabetologia. 2014;57(12):2521-9.

Steck AK, Wong R, Wagner B, et al. Effects of non-HLA gene poly¬morphisms on development of islet autoimmunity and type 1 diabe¬tes in a population with high-risk HLA-DRDQ genotypes. Diabetes. 2012;61(3):753-8.

Bonifacio E, Krumsiek J, Winkler C, Theis FJ, Ziegler AG. A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Dia- betol. 2014;51(3):403-11.

Steck AK, Xu P, Geyer S, et al. Can non-HLA single nucleotide poly¬morphisms help stratify risk in TrialNet relatives at risk for type 1 dia¬betes? JClin Endocrinol Metab. 2017;102(8):2873-80.

Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care. 2016;39(3):337-44.

Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a system¬atic review. Transl Res. 2014;164:110-21.

Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38(6):989-96.

DPT-1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N EngJ Med. 2002;346(22):1685-91.

Xu P, Wu Y, Zhu Y, et al. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care. 2010; 33(12):2508-13.

Xu P, Beam CA, Cuthbertson D, et al. Prognostic accuracy of immu¬nologic and metabolic markers for type 1 diabetes in a high-risk pop¬ulation: receiver operating characteristic analysis. Diabetes Care. 2012;35(10):1975-80.

Sims EK, Chaudhry Z, Watkins R, et al. Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 dia¬betes. Diabetes Care. 2016;39(9):1519-26.

Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685-91.

Steck AK, Dong F, Taki I, Hoffman M, Klingensmith GJ, Rewers MJ. Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes. Diabetes Care. 2014;37(7): 2031-3.

Van Dalem A, Demeester S, Balti EV, et al. Relationship between gly- caemic variability and hyperglycaemic clamp-derived functional vari¬ables in (impending) type 1 diabetes. Diabetologia. 2015;58(12): 2753-64.

Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of child¬hood type 1 diabetes and reduced contribution of high-risk HLA hap¬lotypes. Lancet. 2004;364(9446):1699-700.

Fourlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leuko¬cyte antigen genotypes. Diabetes Care. 2008;31(8):1546-9.

Hermann R, Knip M, Veijola R, et al. Temporal changes in the fre¬quencies of HLA genotypes in patients with type 1 diabetes--indication of an increased environmental pressure? Dia- betologia. 2003;46(3):420-5.

Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabe¬tes. Lancet. 2016;387(10035):2340-8.

McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet.1992;340(8816):414-5.

Takasu N, Ikema T, Komiya I, Mimura G. Forty-year observation of 280 Japanese patients with congenital rubella syndrome. Diabetes Care. 2005;28(9):2331-2.

Yeung G, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus—a systematic review of molecular studies. Br Med J. 2011;342:d35.

Allen DW, Kim KW, Rawlinson WD, Craig ME. Maternal virus infec¬tions in pregnancy and type 1 diabetes in their offspring: systematic review and meta-analysis of observational studies. Rev Med Virol. 2018;28(3):e1974.

Akerblom HK, Virtanen SM, Ilonen J, et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005;48(5):829-37.

Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003; 290(13):1713-20.

Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoanti¬bodies. JAMA. 2003;290(13):1721-8.

Norris JM, Yin X, Lamb MM, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA. 2007;298(12):1420-8.

Tizaoui K, Kaabachi W, Hamzaoui A, Hamzaoui K. Contribution of VDR polymorphisms to type 1 diabetes susceptibility: systematic review of case-control studies and meta-analysis. J Steroid Biochem Mol Biol. 2014;143C:240-9.

Simpson M, Brady H, Yin X, et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoim¬munity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011;54(11):2779-88.

Raab J, Giannopoulou EZ, Schneider S, et al. Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression. Diabetologia. 2014;57(5):902-8.

Couper JJ, Beresford S, Hirte C, et al. Weight gain in early life pre¬dicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care. 2009;32(1):94-9.

Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insu¬lin resistance is a risk factor for progression to type 1 diabetes. Dia-betologia.2004;47(10):1661-7.

Ferrara CT, Geyer SM, Liu YF, et al. Excess BMI in childhood: a modi¬fiable risk factor for type 1 diabetes development? Diabetes Care. 2017;40(5):698-701.

TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study. Ann N YAcad Sci. 2008;1150:1-13.

Penno MA, Couper JJ, Craig ME, et al. Environmental Determinants of Islet Autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes. BMC Pediatr. 2013;13(1):124.

Smith LB, Liu X, Johnson SB, et al. Family adjustment to diabetes diagnosis in children: can participation in a study on type 1 diabetes genetic risk be helpful? Pediatr Diabetes. 2018;19(5):1025-33.

Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301-5.

Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med. 2012;166(7): 608-14.

Akerblom HK, Krischer J, Virtanen SM, et al. The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: recruitment, interven¬tion and follow-up. Diabetologia. 2011;54(3):627-33.

Knip M, Akerblom HK, Becker D, et al. Hydrolyzed infant formula and early p-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311(22):2279-87.

Knip M, Akerblom HK, Al Taji E, et al. Effect of hydrolyzed infant for¬mula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA. 2018;319(1):38-48.

Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the pre-POINT randomized clinical trial. JAMA. 2015; 313(15):1541-9.

Ziegler AG, Danne T, Dunger DB, et al. Primary prevention of beta-cell autoimmunity and type 1 diabetes—the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol Metab. 2016;5(4):255-62.

Larsson PG, Lakshmikanth T, Laitinen OH, et al. A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia. 2015;58(2):346-54.

Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet—an international collaborative clinical trials network. Ann N YAcad Sci. 2008;1150:14-24.

Battaglia M, Anderson MS, Buckner JH, et al. Understanding and pre¬venting type 1 diabetes through the unique working model of Trial- Net. Diabetologia. 2017;60(11):2139-47.

Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004; 363(9413):925-31.

Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in rela¬tives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care. 2005;28(5):1068-76.

Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann N YAcad Sci. 2008;1150:190-6.

Fourlanos S, Perry C, Gellert SA, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune dia¬betes. Diabetes. 2011;60(4):1237-45.

Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care. 2004;27(10):2348-55.

Wilkin T, Greene S, McCrimmon R. Testing the accelerator hypothe¬sis: a new approach to type 1 diabetes prevention (adAPT 1). Diabe¬tes Obes Metab. 2016;18(1):3-5.

Han MX, Craig ME. Research using autologous cord blood—time for a policy change. Med J Aust. 2013;199(4):288-99.

Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclospor¬ine. N Engl J Med. 1988;318(11):663-70.

Beam CA, MacCallum C, Herold KC, et al. GAD vaccine reduces insu¬lin loss in recently diagnosed type 1 diabetes: findings from a Bayes¬ian meta-analysis. Diabetologia. 2017;60(1):43-9.

Vudattu NK, Herold KC. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther. 2014;14(3):377-385.

Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with

abatacept in patients with recent-onset type 1 diabetes: a rando¬mised, double-blind, placebo-controlled trial. Lancet. 2011; 378(9789):412-9.

Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4): 1069-75.

Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285-96.

Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte deple¬tion with rituximab and p-cell function: two-year results. Diabetes Care. 2014;37(2):453-9.

Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes. 2013;62(11): 3901-8.

Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301(15):1573-9.

Haller MJ, Gitelman SE, Gottlieb PA, et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodula¬tory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes. 2016;65(12):3765-75.

Haller MJ, Schatz DA, Skyler JS, et al. Low-dose anti-thymocyte glob¬ulin (ATG) preserves p-cell function and improves HbA. Diabetes Care. 2018;dc180494.

Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378(9788):319-27.

Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881): 1905-15.

Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710-8.

Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab com¬bined therapy in patients with new- onset type 1 diabetes. Diabetes Care. 2010;33(4):826-32.

Brooks-Worrell B, Palmer JP. Prevention versus intervention of type 1 diabetes. Clin Immunol. 2013;149(3):332-8.

Ludvigsson J. Combination therapy for preservation of beta cell func¬tion in type 1 diabetes: new attitudes and strategies are needed! Immunol Lett. 2014;159(1-2):30-5.

Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of dia¬betic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11): 2347-52.

Steck AK, Larsson HE, Liu X, et al. Residual beta-cell function in dia¬betes children followed and diagnosed in the TEDDY study com¬pared to community controls. Pediatr Diabetes. 2017;18(8):794-802.

Winkler C, Schober E, Ziegler AG, Holl RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes. 2012;13(4):308-13.

Triolo TM, Chase HP, Barker JM, DPT-1 Study Group. Diabetic sub¬jects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care. 2009;32(5):769-73.

Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic con¬trol. Diabetes Care. 2017;40:1249-55.

Raab J, Haupt F, Scholz M, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general popula¬tion: design and initial results of the Fr1da study. BMJ Open. 2016; 6(5):e011144.

Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associ¬ated with the presence of diabetic ketoacidosis at diagnosis of diabe¬tes in children and young adults: a systematic review. BMJ. 2011; 343:d4092.

Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(Suppl 12):118-33.

Kapellen TM, Gausche R, Dost A, et al. Children and adolescents with type 1 diabetes in Germany are more overweight than healthy con¬trols: results comparing DPV database and CrescNet database. J Pediatr Endocrinol Metab.2014;27(3-4):209-14.

Islam ST, Abraham A, Donaghue KC, et al. Plateau of adiposity in Australian children diagnosed with type 1 diabetes: a 20-year study. Diabet Med. 2014;31:686-90.

Phelan H, Clapin H, Bruns L Jnr, et al. The Australasian Diabetes Data Network (ADDN): first national audit data on children and adoles¬cents with type 1 diabetes. Med J Aust. 2017;206(3):121-5.

Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospec¬tive evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: thekey-role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4): 246-51.

Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008;57(11):2883-8.

Shields BM, McDonald TJ, Oram R, et al. C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subse¬quent stable phase. Diabetes Care. 2018;41(7):1486-92.

The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A ran¬domized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998;128(7):517-23.

Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832-6.

Bober E, Dundar B, Buyukgebiz A. Partial remission phase and meta¬bolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14(4):435-41.

Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and ado¬lescents (>12 yr) with type 1 diabetes mellitus have low rate of par¬tial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008;9(3 Pt 1):197-201.

Mortensen HB, Hougaard P, Swift P, et al. New definition for the partial remission period in children and adolescents with type 1 dia¬betes. Diabetes Care. 2009;32(8):1384-90.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ, Group TDTS. Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care. 2016;39(10):1664-70.

Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187-91.

Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabe¬tes. Diabetes Care. 2015;38(3):476-81.